Bone News and Research

RSS

Eli Lilly, Synthes collaborate to develop osteoinductive products

Synthes, Inc. and Eli Lilly and Company today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.

10 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011

Decline of citrate concentration may contribute to bone brittleness

Bone is one of nature's surprising "building materials." Pound-for-pound it's stronger than steel, tough yet resilient. Scientists at the U.S. Department of Energy's Ames Laboratory have identified the composition that gives bone its outstanding properties and the important role citrate plays, work that may help science better understand and treat or prevent bone diseases such as osteoporosis.

9 Jun 2011

Single molecule telomerase activator could extend human cell life indefinitely

When expressed (turned on), the gene (hTERT) located on Chromosome number 5p15.33 activates the enzyme telomerase. Human cells can keep living and dividing indefinitely when telomerase is continually present; i.e. the cells become immortal. Telomerase Activation Sciences, Inc. (T.A. Sciences®) announces TA-65® can extend human cell life indefinitely. TA-65® is a single molecule telomerase activator that turns on the Immortality Gene under controlled laboratory conditions.

8 Jun 2011

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) has unanimously recommended termination of the study.

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Cabozantinib shows early promise in treatment of prostate cancer spread to the bone

A new drug to treat prostate cancer shows early promise, particularly against tumors that have spread to the bone, a multi-site study shows.

8 Jun 2011

Patient enrollment complete in BioMimetic's Augment Rotator Cuff pilot trial

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears.

8 Jun 2011

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.

8 Jun 2011

As health care technology advances, costs increase

The device industry has launched an aggressive campaign to avoid tighter Food and Drug Administration rules that would help generate the information needed to show whether newer devices are actually superior to the ones they replace.

8 Jun 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

7 Jun 2011

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

7 Jun 2011

$Zoledronate at lower dose effective in reducing risk of osteoporotic fractures$

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds.

7 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

The Endocrine Society releases clinical practice guideline on Vitamin D deficiency

Today, The Endocrine Society released "Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline." The clinical practice guideline (CPG) is published in the July 2011 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.

7 Jun 2011

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

7 Jun 2011

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Researchers in the Department of Pathology at Stony Brook University School of Medicine have discovered a laboratory method to expand adult hematopoietic stem cells (HSCs) using the SALL4 gene. Professor Yupo Ma, M.D., Ph.D., Lead Author, and colleagues used this method to produce a more than 10,000-fold increase in HSCs derived from normal human bone marrow.

7 Jun 2011

Bone News and Research

Eli Lilly, Synthes collaborate to develop osteoinductive products

Article reports on bright future and enormous need for stem cell therapeutics

Decline of citrate concentration may contribute to bone brittleness

Single molecule telomerase activator could extend human cell life indefinitely

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Cabozantinib shows early promise in treatment of prostate cancer spread to the bone

Patient enrollment complete in BioMimetic's Augment Rotator Cuff pilot trial

Bio-Nucleonics resumes production of metastatic cancer drug, Strontium-89

As health care technology advances, costs increase

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Zoledronate at lower dose effective in reducing risk of osteoporotic fractures

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

The Endocrine Society releases clinical practice guideline on Vitamin D deficiency

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News